Warning Letter Reveals FDA's Part 11 Enforcement Stance

Drug GMP Report
KEYWORDS FDA / Part 11 / Warning

A recent warning letter citing 21 CFR Part 11 validation and control requirements sends a clear signal that the FDA intends to enforce the electronic records and signatures rule even as the agency moves toward revising it, industry experts say.

To View This Article:


Subscribe To Drug GMP Report

Buy This Article Now

Add this article to your cart for $10.00